Although new therapies developed in the laboratory are showing promising and exciting results, their translation to patients has not lived up to expectations. This not surprising as in the laboratory therapies are directly tested with target cells.

However, in real life, therapies are usually administered to patients by an intravenous injection resulting in the whole body being exposed to a therapy with only a small amount reaching a target organ.

IRIS is leading the way to preclinically develop, and clinically translate, techniques and strategies for the precision delivery of patient-specific therapies to any location in the human body.

Given our disease agnostic approach, we focus on each organ system separately to develop “out-of-the-box delivery strategies” that use novel innovative technologies to (i) gain access to organ and (ii) modulate their microenvironment making them receptive to therapies.

Interventional Radiologists are uniquely positioned to pioneer this initiative given they are delivery specialist physicians who can access any part of the human body, using non-surgical minimally invasive techniques, guided by advanced imaging.